Presentation

0 Comments

18 December 2016

Moderating the risk of ACS patients by early decisions on platelet ‎inhibition

Dr Jörg M Rustige

Correvio International, Switzerland

Previous | Next
Download

Summary

Dr Jorg M Rustige discusses the role of GPIIb/IIIa inhibitors in high-risk PCI. He discussed On-TIME 2 trail and concludes that early platelet inhibition by administering IV Tirofiban with a high dose bolus reduces major cardiovascular events at 30 days and 1 year in STEMI and high-risk NSTE-ACS patients with a modest increase in bleeding complications.

Download

Summary

Dr Jorg M Rustige discusses the role of GPIIb/IIIa inhibitors in high-risk PCI. He discussed On-TIME 2 trail and concludes that early platelet inhibition by administering IV Tirofiban with a high dose bolus reduces major cardiovascular events at 30 days and 1 year in STEMI and high-risk NSTE-ACS patients with a modest increase in bleeding complications.

You have to be a BCIS member to access this content

Either Sign in or register to become a member, today! Join BCIS Sign In